Skip to main content
. 2021 Aug 20;13(8):1300. doi: 10.3390/pharmaceutics13081300

Figure 4.

Figure 4

ATR-FTIR analysis of (A) CUR formulation and its components: raw powder (a), P188 (b). physical mixture of CUR+P188 (c), CUR-NS (d); and (B) BDP formulation and its components: raw powder (e), physical mixture of BDP+P188 (f), and BDP-NS (g).